Figure 4.

Combination of Chemotherapy with Systemic Application of CAR T Cells

(A) Schematic of combination therapy. 5- to 6-week-old SCID mice were injected subcutaneously (s.c.) with 1.5 × 10⁶ C4-2^luc+ tumor cells. When tumors reached a mean tumor volume of 150–200 mm³, mice were treated intraperitoneally (i.p.) with two cycles of DTX (6 mg/kg body weight [bw]) at days 1 and 2 of treatment. At day 8, mice received one i.v. dose of 5 × 10⁶ CAR28 (n = 9) or CAR41 T cells (n = 8). As controls, mice were injected with DTX alone (DTX, n = 9) or left untreated (control, n = 8). (B) In vivo monitoring. Shown are representative in vivo bioluminescence images (BLIs) of mice in different treatment groups. (C) Quantification of tumor size. Tumor volumes were determined on days 1, 8, 15, 17, and 22 of treatment. ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, by unpaired t test.